The average 12-month target price among brokers that have issued a report on the stock in the last year is $15.82. Boston Scientific has a one-year low of $11.10 and a one-year high of $15.28. The company has a market cap of $19.474 billion.
Additionally, Boston Scientific Executive Vice President Joseph Michael Fitzgerald sold 61,208 shares of the stock on the open market in a transaction on Feb. 10, for a total value of approximately $897,309, according to the report.
More articles on GI/endoscopy:
Male & female active physicians: 70 statistics by specialty
Opinion: Advances in HCV treatment underutilized due to barriers
Chromoendoscopy could boost ADR in Lynch syndrome
